| Literature DB >> 35174029 |
Manaswinee Mallik1, Abhishek Singhai1, Sagar Khadanga2, Vaibhav Ingle3.
Abstract
BACKGROUND: Cirrhosis progression varies greatly from patient to patient due to a variety of factors, including hepatic reserve, cirrhosis etiology, and the presence of hepatocellular cancer. As a result, determining a prognosis in a patient with cirrhosis remains a difficult task. For nearly three decades, the Child-Pugh score (CPS) has been the gold standard for determining the prognosis of cirrhosis. In the last two decades, many prognostic models and scores like a model for end-stage liver disease (MELD), chronic liver failure-sequential organ failure assessment (CLIF-SOFA) score, peripheral blood lymphocyte to monocyte ratio (LMR) have been presented to predict prognosis in patients with cirrhosis and to choose the best therapy option. The aim of our study is to determine which score is more effective in predicting three-month mortality and whether these scores are equally effective in predicting short-term outcomes. MATERIALS &Entities:
Keywords: child-pugh score; cirrhosis; meld score; morbidity; mortality
Year: 2022 PMID: 35174029 PMCID: PMC8841014 DOI: 10.7759/cureus.21226
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Characteristics of the study population, difference between the variables among non-survivors and survivors patients
*Independent t-test, ‡ Fisher's exact test, § Chi-square test, **Mann Whitney U test
NASH - nonalcoholic steatohepatitis; INR - international normalized ratio; MELD score - model for end-stage liver disease score; LMR - lymphocyte to monocyte ratio; CLIF SOFA - chronic liver failure-sequential organ failure assessment
| Variables | Study subject (n=140) | Non-surviving (n=65) | Surviving (n=75) | P-value |
| Female/male | 34 (24.29%)/106 (75.71%) | 12 (35.29%)/53 (50%) | 22 (64.71%)/53 (50%) | 0.135§ |
| Age (years) (Mean+SD) | 47.75± 13 | 47.91 ± 12.89 | 47.61 ± 13.18 | 0.894* |
| Illiterate/literate | 108 (77.14%)/32 (22.86%) | 13 (40.63%)/52 (48.15%) | 19 (59%)/56 (51.85%) | 0.454§ |
| Etiology | ||||
| Alcohol-related | 64 (45.71%) | 33 (51.56%) | 31 (48.44%) | 0.548‡ |
| Hepatitis B | 24 (17.14%) | 9 (37.50%) | 15 (62.50%) | |
| Hepatitis C | 11 (7.86%) | 7 (63.64%) | 4 (36.36%) | |
| NASH | 12 (8.57%) | 4 (33.33%) | 8 (66.67%) | |
| Cardiac | 9 (6.43%) | 5 (55.56%) | 4 (44.44%) | |
| Budd chiarisyndrome | 3 (2.14%) | 1 (33.33%) | 2 (66.67%) | |
| Biliary | 4 (2.86%) | 1 (25%) | 3 (75%) | |
| Autoimmune | 6 (4.29%) | 3 (50%) | 3 (50%) | |
| Wilson disease | 1 (0.71%) | 1 (100%) | 0 (0%) | |
| Cryptogenic | 6 (4.29%) | 1 (16.67%) | 5 (83.33%) | |
| Duration since diagnosis (months) (Median) | 6 (0-12) months | 6 (0-24) | 6 (0-12) | 0.621** |
| Total protein (g/dL) (mean±SD) | 6.18 ± 0.95 | 6.04 ± 0.92 | 6.3 ± 0.97 | 0.116* |
| Albumin (g/dL) (Median) | 2.51 (2.078-2.907) | 2.2 (1.95-2.59) | 2.82 (2.195-3.2) | <0.0001> |
| Total bilirubin (mg/dL) (Median) | 2.08 (1.008-5.098) | 4.12 (1.76-8.32) | 1.36 (0.89-2.675) | <0.0001> |
| Creatinine (mg/dL) (Median) | 1.02 (0.8-1.592) | 1.22 (0.89-2.01) | 0.9 (0.725-1.26) | 0.002** |
| INR (Median) | 1.46 (1.218-1.79) | 1.67 (1.39-2.3) | 1.3 (1.15-1.535) | <0.0001> |
| Total leukocyte count (10^3cells/mL) (Median) | 7.4 (4.995-10.212) | 8.02 (6.31-10.9) | 6.62 (4.725-9.795) | 0.005** |
| Platelets (Median) (10^3cells/mL) | 116 (68.75-177.75) | 104 (65-175) | 120 (73-180.5) | 0.516** |
| Absolute monocyte count 10^3cells/mL) (Median) | 0.53 (0.314-0.9) | 0.69 (0.46-1.09) | 0.4 (0.251-0.7) | <0.0001> |
| Absolute lymphocyte count (10^3cells/mL)(Median) | 1.12 (0.77-1.702) | 1.04 (0.782-1.52) | 1.15 (0.72-1.775) | 0.638** |
| Child-Pugh class (Median) | 9 (7-11) | 11 (9-12) | 8 (7-9) | <0.0001> |
| Child-Pugh class A | 13 (9.29%) | |||
| Child-Pugh class B | 66 (47.14%) | |||
| Child-Pugh class C | 61 (43.57%) | |||
| MELD score (Median) | 13.54 (8.718-22.033) | 21.03 (12.17-27.42) | 10.36(7.4-14.6) | <0.0001> |
| LMR score (Median) | 1.96 (1.198-3.028) | 1.38 (0.93-2.26) | 2.57 (1.73-4.325) | <0.0001> |
| CLIF-SOFA score (Median) | 5 (3-7) | 3 (2-5) | 7 (5-10) | <0.0001> |
Receiver operating characteristic curve of CPS, MELD, LMR, and CLIF-SOFA score to predict mortality
ROC - Receiver operating curve; PPV - positive predictive value; NPV - negative predictive value
| Mortality | Child-Pugh score (CPS) class | Model for end-stage liver disease (MELD) score | Lymphocyte to Monocyte Ratio (LMR) | Chronic liver failure-sequential organ failure assessment (CLIF-SOFA) |
| Area under the ROC curve (AUC) | 0.792 | 0.765 | 0.75 | 0.808 |
| Standard Error | 0.0338 | 0.0417 | 0.0407 | 0.0373 |
| 95% Confidence interval | 0.716 to 0.856 | 0.685 to 0.832 | 0.669 to 0.819 | 0.733 to 0.870 |
| P-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Cut off | >B | >20.49 | ≤1.66 | >5 |
| Sensitivity (95% CI) | 72.31% (59.8%-82.7%) | 55.38% (42.5%-67.7%) | 61.54% (48.6%-73.3%) | 70.77% (58.2%-81.4%) |
| Specificity (95% CI) | 81.33% (70.7%-89.4%) | 93.33% (85.1%-97.8%) | 76% (64.7%-85.1%) | 81.33% (70.7%-89.4%) |
| PPV (95% CI) | 77% (64.5%-86.8%) | 87.8% (73.8%-95.9%) | 69% (55.5%-80.5%) | 76.7% (64.0%-86.6%) |
| NPV (95% CI) | 77.2% (66.4%-85.9%) | 70.7% (60.7%-79.4%) | 69.5% (58.4%-79.2%) | 76.2% (65.4%-85.1%) |
| Diagnostic accuracy | 77.14% | 75.71% | 69.29% | 76.43% |
Figure 1Receiver operating curve of various prediction scores for three months mortality as an outcome
MELD score - model for end-stage liver disease score; LMR - lymphocyte to monocyte ratio; CLIF SOFA - chronic liver failure-sequential organ failure assessment
Difference in variables between non-surviving and surviving patients
*Independent t-test, ‡ Fisher's exact test, § Chi-square test, **Mann Whitney U test
NASH - nonalcoholic steatohepatitis; INR - international normalized ratio; CPS - Child-Pugh score; MELD score - model for end-stage liver disease score; LMR - lymphocyte to monocyte ratio; CLIF SOFA - chronic liver failure-sequential organ failure assessment
| Variables | Non-surviving (n=65) | Surviving (n=75) | P-value |
| Female/male | 12/53 | 22/53 | 0.135§ |
| Ag e(years) | 47.91 ± 12.89 | 47.61 ± 13.18 | 0.894* |
| Illiterate /literate | 13/52 | 19/56 | 0.454§ |
| Etiology | |||
| Alcohol-related | 33 | 31 | 0.548‡ |
| Hepatitis B | 9 | 15 | |
| Hepatitis C | 7 | 4 | |
| NASH | 4 | 8 | |
| Cardiac | 5 | 4 | |
| Budd Chiari syndrome | 1 | 2 | |
| Biliary | 1 | 3 | |
| Autoimmune | 3 | 3 | |
| Wilson disease | 1 | 0 | |
| Cryptogenic | 1 | 5 | |
| Duration since diagnosis (months) | 6 (0-24) | 6 (0-12) | 0.621** |
| Total protein (g/dL) | 6.04 ± 0.92 | 6.3 ± 0.97 | 0.116* |
| Albumin (g/dL) | 2.2 (1.95-2.59) | 2.82 (2.195-3.2) | <0.0001> |
| Total bilirubin (mg/dL) | 4.12 (1.76-8.32) | 1.36 (0.89-2.675) | <0.0001> |
| Creatinine (mg/dL) | 1.22 (0.89-2.01) | 0.9 (0.725-1.26) | 0.002** |
| INR | 1.67 (1.39-2.3) | 1.3 (1.15-1.535) | <0.0001> |
| Total leukocyte count (103cells/mL) | 8.02 (6.31-10.9) | 6.62 (4.725-9.795) | 0.005** |
| Platelets (103cells/mL) | 104 (65-175) | 120 (73-180.5) | 0.516** |
| Absolute monocyte count (103cells/mL) | 0.69 (0.46-1.09) | 0.4 (0.251-0.7) | <0.0001> |
| Absolute lymphocyte count (103cells/mL) | 1.04 (0.782-1.52) | 1.15 (0.72-1.775) | 0.638** |
| CPS | 11 (9-12) | 8 (7-9) | <0.0001> |
| MELD | 21.03 (12.17-27.42) | 10.36 (7.4-14.6) | <0.0001> |
| LMR | 1.38 (0.93-2.26) | 2.57 (1.73-4.325) | <0.0001> |
| CLIF-SOFA | 3 (2-5) | 7 (5-10) | <0.0001> |